reports
- Abe Rimatzki
- Seth Basham
CECO Environmental to Release Second Quarter Earnings and Host Confere...
CECO Environmental to Release Second Quarter Earnings and Host Conference Call on July 29 ADDISON, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it will report its second quarter of 2025 financial results on July 29, 2025, premarket. The Company will also host its earnings call starting at 8:30 a.m. Eastern Time (7:30 a.m. CT). The Company’s financial results and presentation will be posted on i...
- Wedbush Research
PEGA PEGASYSTEMS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CVCO CAVCO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
TTD THE TRADE DESK
INC.
- Dylan Shindler
- Laura Chico
Integra LifeSciences to Host Second Quarter 2025 Financial Results Con...
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025 PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register to receive dial-in...
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA Nat...
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. “For more than a decade, we have been...
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corp...
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. “Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual ...
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PZG PARAMOUNT GOLD NEVADA CORP.
IRIX IRIDEX CORP.
VFF VILLAGE FARMS INTERNATIONAL IN
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
GRF ASTRONOVA INC.
NHF EAGLE CAPITAL GROWTH FUND INC
BCBP NEXPOINT CREDIT STRATEGIES FUN
RSSS BCB BANCORP INC.
NWPP RESEARCH SOLUTIONS
RFL NEW PEOPLES BANKSHARES INC.
ULBI RAFAEL HOLDINGS CL B
YMAB ULTRALIFE
IMUX Y-MABS THERAPEUTICS
AMPY IMMUNIC INC
INLX AMPLIFY ENERGY
ENX INTELLINETICS
DLHC INC.
COOK EATON VANCE NEW YORK MUNICIPAL BOND FUND
IMRX DALEIGH HOLDINGS CORP
XLO TRAEGER
NVCT INC.
GECC IMMUNEERING CORP
BARK XILIO THERAPEUTICS INC
NNUP NUVECTIS PHARMA INC
ERNA GREAT ELM CAPITAL CORP
GTE ORIGINAL BARK CO
GENK NOCOPI TECHS INC
SRBK ETERNA THERAPEUTICS INC.
NKGN GRAN TIERRA ENERGY INC.
PROP GEN RESTAURANT GROUP INC
ACTU SR BANCORP INC
SUNS NKGEN BIOTECH INC
EVM PRAIRIE OPERATING CO.
MBRX ACTUATE THERAPEUTICS INC.
SLS SUNRISE REALTY TRUST
WHLR EATON VANCE INSD CALIF MUN BD FD
HYMC MOLECULIN BIOTECH INC.
THAR SELLAS LIFE SCIENCES GROUP INC
RVYL WHEELER REAL ESTATE INVESTMENT TRUST INC.
INUV HYCROFT MINING HOLDING CORPORATION
CCIF THARIMMUNE INC.
RYVYL INC.
INUVO INC.
CARLYLE CREDIT INCOME FUND
Integra LifeSciences Announces First Patient Enrolled in Acclarent AER...
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world clinical performance of AERA in pediatric patients with obstructive Eustachian tube dysfunction (ETD). Dr....
- Wedbush Research
MNKD MANNKIND CORP.
GOOGL ALPHABET INC. CLASS A
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
PTGX PROTAGONIST THERAPEUTICS
ZG ZILLOW GROUP INC. CLASS A
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
COGT COGENT BIOSCIENCES INC
RKT ROCKET COMPANIES
APGE APOGEE THERAPEUTICS INC
- Dylan Shindler
- Laura Chico
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business ...
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from pr...
- Dylan Shindler
- Laura Chico
- Jonathan Moreland
MTX MINERALS TECHNOLOGIES INC.
BUSE FIRST BUSEY CORPORATION
FLL FULL HOUSE RESORTS INC.
ALOT
MLP ASTRONOVA INC.
NWPP MAUI LAND & PINEAPPLE CO. INC.
BHC NEW PEOPLES BANKSHARES INC.
DLHC BAUSCH HEALTH COMPANIES INC.
MNR DALEIGH HOLDINGS CORP
SUNS MACH NATURAL RESOURCES LP
HYMC SUNRISE REALTY TRUST
HYCROFT MINING HOLDING CORPORATION
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORL...
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI —Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
LINC LINCOLN EDUCATIONAL SERVICES
IMAX IMAX CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
PATK PATRICK INDUSTRIES INC.
MEG. MEG ENERGY CORP.
HRTG HERITAGE INSURANCE HOLDINGS INC.
ELF E.L.F. BEAUTY INC.
PAYS PAYSIGN INC
RPRX ROYALTY PHARMA PLC CLASS A
IMTX IMMATICS N V (A)
CVAC CUREVAC NV
IHS IHS HLDG LTD
SGHC SUPER GROUP (SGHC) LIMITED
CMPO COMPOSECURE INC
FTREV FORTREA HOLDINGS INC.
SGMT SAGIMET BIOSCIENCES INC
PC PREMIUM CATERING HOLDINGS LIMITED
ORLADEYO® (berotralstat) Approved in Colombia
ORLADEYO® (berotralstat) Approved in Colombia RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “Today’s announcement marks another important step toward bringing ORLADEYO to people living with HAE who are in need of new treatment options across the pan-Latin America region. Followin...
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European...
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.